The rapid expansion of legal cannabis markets has created a significant blind spot in public health surveillance, potentially obscuring a growing population requiring addiction treatment services. While regulatory frameworks excel at tracking consumption patterns and product potency, they remain poorly equipped to identify individuals experiencing clinically meaningful harm from cannabis use.
This comprehensive review reveals that current epidemiological methods capture cannabis exposure with unprecedented precision but demonstrate limited sensitivity for detecting persistent impairment or treatment-worthy disorders. The transition from DSM-IV to DSM-5 diagnostic criteria has fundamentally altered how cannabis use disorder (CUD) is classified and measured in population surveys, complicating longitudinal trend analysis precisely when such data becomes most critical for policy evaluation.
The disconnect between surveillance capabilities and clinical reality reflects a broader challenge facing post-legalization jurisdictions: commercial cannabis markets are evolving faster than treatment infrastructure can adapt. Evidence-based interventions for CUD exist, including cognitive-behavioral therapy and contingency management, yet treatment system capacity remains inadequate to meet emerging demand.
This surveillance gap represents more than an academic concern—it suggests that jurisdictions implementing cannabis legalization may be operating with incomplete information about population-level harm. The review highlights how diagnostic framework changes, measurement limitations, and treatment capacity constraints collectively impair our ability to understand and respond to cannabis-related disorders in an era of unprecedented product availability and potency. For health-conscious adults, this analysis underscores the importance of self-monitoring cannabis use patterns, particularly given the documented increases in high-THC product availability following legalization.